# GRK5

## Overview
The GRK5 gene encodes the protein G protein-coupled receptor kinase 5 (GRK5), which is a member of the kinase family involved in the regulation of G protein-coupled receptors (GPCRs). GRK5 plays a pivotal role in cellular signaling by phosphorylating activated GPCRs, thereby facilitating receptor desensitization and modulating downstream signaling pathways. This kinase is characterized by its modular structure, including a kinase domain and a regulator of G protein signaling (RGS) domain, which are essential for its function and localization (Komolov2015Atomic; Xu2014The). GRK5 is implicated in various physiological and pathological processes, including cardiovascular regulation, neurodegenerative diseases, and metabolic disorders, making it a significant target for therapeutic intervention (Arawaka2006The; Hendrickx2018GRK5).

## Structure
The GRK5 protein is a member of the G protein-coupled receptor kinase family, characterized by a modular structure that includes a kinase domain and a regulator of G protein signaling (RGS) domain. The kinase domain of GRK5 features a bilobal fold with a smaller N-terminal lobe (N-lobe) and a larger C-terminal lobe (C-lobe). The N-lobe consists of a five-strand anti-parallel β sheet and flanking helices αB and αC, while the C-lobe contains a two-strand antiparallel β sheet and six α helices (αD-αI) (Komolov2015Atomic). The RGS domain is crucial for plasma membrane localization and dimerization, which is important for its function (Xu2014The).

GRK5 can form homodimers, although it is typically monomeric in solution. Dimerization may occur in the presence of membranes and interacting proteins (Xu2014The). The protein's structure is stabilized by ligands such as AMP-PNP and sangivamycin, with the latter inducing significant stabilization (Komolov2015Atomic). GRK5 undergoes post-translational modifications, including phosphorylation and palmitoylation, which influence its activity and membrane localization (Komolov2015Atomic). The interaction with calmodulin (CaM) triggers conformational changes, highlighting the structural plasticity of GRK5 (Komolov2021Structure).

## Function
GRK5 is a member of the G protein-coupled receptor kinase family, which plays a crucial role in the phosphorylation and regulation of G protein-coupled receptors (GPCRs) in healthy human cells. This kinase is primarily localized at the plasma membrane, where it exists in a dynamic equilibrium between inactive and active conformations. Activation of GRK5 is driven by the ordering of its N-terminal α-helix, which is stabilized by activators such as GPCRs or calmodulin (CaM) (Komolov2021Structure).

Upon GPCR stimulation, GRK5 binds to the receptor, promoting its active conformation and facilitating receptor phosphorylation. This process is essential for the desensitization of GPCR signaling, preventing excessive cellular responses to stimuli (Xu2014The). GRK5 also phosphorylates non-receptor substrates, such as α-synuclein, in the cytosol, linking changes in intracellular calcium levels to its activity (Komolov2021Structure).

GRK5 is involved in the regulation of various cellular signaling pathways, including the Toll-receptor-4-linked NFκB pathway, where it acts as a positive regulator. It also participates in the phosphorylation of nuclear proteins, such as class II histone deacetylases (HDACs) and transcription factors, impacting processes like inflammation and cytoskeletal dynamics (Gurevich2012G).

## Clinical Significance
The GRK5 gene is implicated in various diseases due to mutations, altered expression levels, or changes in its interactions. In cardiovascular diseases, GRK5 is highly expressed in the myocardium and is involved in regulating cardiac GPCR responsiveness. Alterations in GRK5 expression are linked to myocardial ischemia, myocardial infarction, hypertension, and heart failure. In heart failure, GRK5 is up-regulated, contributing to β-adrenergic receptor desensitization and affecting cardiac contractility (Hullmann2016The; Hendrickx2018GRK5).

In neurodegenerative disorders, GRK5 is associated with Alzheimer's disease (AD) and Parkinson's disease (PD). In AD, GRK5 deficiency is linked to increased amyloidosis and synaptic dysfunction, while in PD, GRK5 phosphorylates α-synuclein, promoting its aggregation in Lewy bodies, a hallmark of the disease (Arawaka2006The; Hendrickx2018GRK5).

GRK5 also plays a role in metabolic disorders such as type 2 diabetes mellitus (T2DM), where its genetic polymorphisms influence insulin signaling and antidiabetic treatment efficacy (Hendrickx2018GRK5). In cancer, GRK5's expression and activity are altered, affecting cell cycle regulation and tumor progression (Marzano2021Targeting). These diverse roles make GRK5 a potential therapeutic target across multiple disease states.

## Interactions
GRK5 (G protein-coupled receptor kinase 5) is involved in a variety of interactions with other proteins and nucleic acids, influencing numerous cellular processes. GRK5 interacts with calmodulin (CaM), a calcium-binding messenger protein, which plays a crucial role in modulating GRK5's activity. This interaction is calcium-dependent and involves two distinct CaM-binding sites on GRK5, located in its N-terminal and C-terminal domains. The binding of CaM to GRK5 can lead to conformational changes that affect its function, including its translocation from the plasma membrane to the nucleus in cardiac myocytes, a process important for cardiac hypertrophy (Levay1998Localization; Gold2013Nuclear).

GRK5 also forms complexes with other proteins, such as G protein-coupled receptors (GPCRs), and is involved in their phosphorylation, which is essential for receptor desensitization. The interaction with GPCRs and CaM involves specific structural domains that regulate GRK5's activation and substrate targeting (Komolov2021Structure). Additionally, GRK5 interacts with phospholipids, which may enhance its membrane association and function (Komolov2021Structure). These interactions highlight GRK5's role in various signaling pathways and its potential impact on cellular functions.


## References


[1. (Gurevich2012G) Eugenia V. Gurevich, John J.G. Tesmer, Arcady Mushegian, and Vsevolod V. Gurevich. G protein-coupled receptor kinases: more than just kinases and not only for gpcrs. Pharmacology &amp; Therapeutics, 133(1):40–69, January 2012. URL: http://dx.doi.org/10.1016/j.pharmthera.2011.08.001, doi:10.1016/j.pharmthera.2011.08.001. This article has 501 citations.](https://doi.org/10.1016/j.pharmthera.2011.08.001)

[2. (Levay1998Localization) Konstantin Levay, Daulet K. Satpaev, Alexey N. Pronin, Jeffrey L. Benovic, and Vladlen Z. Slepak. Localization of the sites for ca2+-binding proteins on g protein-coupled receptor kinases. Biochemistry, 37(39):13650–13659, September 1998. URL: http://dx.doi.org/10.1021/bi980998z, doi:10.1021/bi980998z. This article has 61 citations and is from a peer-reviewed journal.](https://doi.org/10.1021/bi980998z)

[3. (Hullmann2016The) Jonathan Hullmann, Christopher J. Traynham, Ryan C. Coleman, and Walter J. Koch. The expanding grk interactome: implications in cardiovascular disease and potential for therapeutic development. Pharmacological Research, 110:52–64, August 2016. URL: http://dx.doi.org/10.1016/j.phrs.2016.05.008, doi:10.1016/j.phrs.2016.05.008. This article has 52 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1016/j.phrs.2016.05.008)

[4. (Komolov2015Atomic) Konstantin E. Komolov, Anshul Bhardwaj, and Jeffrey L. Benovic. Atomic structure of grk5 reveals distinct structural features novel for g protein-coupled receptor kinases. Journal of Biological Chemistry, 290(34):20629–20647, August 2015. URL: http://dx.doi.org/10.1074/jbc.m115.647297, doi:10.1074/jbc.m115.647297. This article has 33 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1074/jbc.m115.647297)

[5. (Gold2013Nuclear) Jessica I. Gold, Jeffrey S. Martini, Jonathan Hullmann, Erhe Gao, J. Kurt Chuprun, Linda Lee, Douglas G. Tilley, Joseph E. Rabinowitz, Julie Bossuyt, Donald M. Bers, and Walter J. Koch. Nuclear translocation of cardiac g protein-coupled receptor kinase 5 downstream of select gq-activating hypertrophic ligands is a calmodulin-dependent process. PLoS ONE, 8(3):e57324, March 2013. URL: http://dx.doi.org/10.1371/journal.pone.0057324, doi:10.1371/journal.pone.0057324. This article has 58 citations and is from a peer-reviewed journal.](https://doi.org/10.1371/journal.pone.0057324)

[6. (Hendrickx2018GRK5) Jhana O. Hendrickx, Jaana van Gastel, Hanne Leysen, Paula Santos-Otte, Richard T. Premont, Bronwen Martin, and Stuart Maudsley. Grk5 – a functional bridge between cardiovascular and neurodegenerative disorders. Frontiers in Pharmacology, December 2018. URL: http://dx.doi.org/10.3389/fphar.2018.01484, doi:10.3389/fphar.2018.01484. This article has 19 citations and is from a peer-reviewed journal.](https://doi.org/10.3389/fphar.2018.01484)

[7. (Marzano2021Targeting) Federica Marzano, Antonio Rapacciuolo, Nicola Ferrara, Giuseppe Rengo, Walter J. Koch, and Alessandro Cannavo. Targeting grk5 for treating chronic degenerative diseases. International Journal of Molecular Sciences, 22(4):1920, February 2021. URL: http://dx.doi.org/10.3390/ijms22041920, doi:10.3390/ijms22041920. This article has 15 citations and is from a peer-reviewed journal.](https://doi.org/10.3390/ijms22041920)

[8. (Xu2014The) Hua Xu, Xiaoshan Jiang, Ke Shen, Christopher C. Fischer, and Philip B. Wedegaertner. The regulator of g protein signaling (rgs) domain of g protein–coupled receptor kinase 5 (grk5) regulates plasma membrane localization and function. Molecular Biology of the Cell, 25(13):2105–2115, July 2014. URL: http://dx.doi.org/10.1091/mbc.E13-09-0547, doi:10.1091/mbc.e13-09-0547. This article has 21 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1091/mbc.E13-09-0547)

[9. (Arawaka2006The) Shigeki Arawaka, Manabu Wada, Saori Goto, Hiroki Karube, Masahiro Sakamoto, Chang-Hong Ren, Shingo Koyama, Hikaru Nagasawa, Hideki Kimura, Toru Kawanami, Keiji Kurita, Katsushi Tajima, Makoto Daimon, Masanori Baba, Takashi Kido, Sachiko Saino, Kaoru Goto, Hironobu Asao, Chihumi Kitanaka, Emi Takashita, Seiji Hongo, Takao Nakamura, Takamasa Kayama, Yoshihiro Suzuki, Kazuo Kobayashi, Tadashi Katagiri, Katsuro Kurokawa, Masayuki Kurimura, Itaru Toyoshima, Kazuhiro Niizato, Kuniaki Tsuchiya, Takeshi Iwatsubo, Masaaki Muramatsu, Hiroto Matsumine, and Takeo Kato. The role of g-protein-coupled receptor kinase 5 in pathogenesis of sporadic parkinson’s disease. The Journal of Neuroscience, 26(36):9227–9238, September 2006. URL: http://dx.doi.org/10.1523/JNEUROSCI.0341-06.2006, doi:10.1523/jneurosci.0341-06.2006. This article has 169 citations.](https://doi.org/10.1523/JNEUROSCI.0341-06.2006)

[10. (Komolov2021Structure) Konstantin E. Komolov, Sarah M. Sulon, Anshul Bhardwaj, Siri C. van Keulen, Nguyen Minh Duc, Daniela K. Laurinavichyute, Hua Jane Lou, Benjamin E. Turk, Ka Young Chung, Ron O. Dror, and Jeffrey L. Benovic. Structure of a grk5-calmodulin complex reveals molecular mechanism of grk activation and substrate targeting. Molecular Cell, 81(2):323-339.e11, January 2021. URL: http://dx.doi.org/10.1016/j.molcel.2020.11.026, doi:10.1016/j.molcel.2020.11.026. This article has 16 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1016/j.molcel.2020.11.026)